Autoimmune factor VIII inhibitors

Current Opinion in Hematology

Volumn 6, Issue 5, 1999, Pages 314-322

  Pruthi, R K ^a   Nichols, W L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ACTIVATED PROTHROMBIN COMPLEX; AUTOPLEX T; AZATHIOPRINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9A; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANEMIA; ANTIBODY TITER; AUTOIMMUNE DISEASE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; ECCHYMOSIS; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW;

AUTOANTIBODIES; FACTOR VIII; HEMOPHILIA A; HUMAN;

EID: 0033302945     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199909000-00008     Document Type: Review

References (52)

1. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients
2. Analysis of Factor VIII inhibitors using hybrid human/porcine factor VIII
3. Mechanism of factor VIII inactivation by human antibodies: IV: Antibody binding prevents factor VIII proteolysis by thrombin
4. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor
5. The molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind the factor VIII light chain prevent the interaction of factor VIII with phospholipid
6. Synthetic factor VIII peptides with amino acid sequence contained within C2 domain factor VIII inhibits factor VIII binding to phosphatidylserine
7. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloanti-body recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
8. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2
9. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition
10. Some human inhibitor antibodies interfere with factor VIII binding to factor IX
11. Factor VIII inhibitors: Structure and function n autoantibody and hemophilia A patients
12. Factor VIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting
13. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction
14. The mode of action of antibodies which destroy factor VIII: I: Antibodies which have second-order concentration graphs
15. Why do some haemophiliacs develop inhibitors?
16. The mode of action of antibodies which destroy factor VIII: II: Antibodies which give complex concentration graphs
17. Inactivation of factor VIII coagulant activity by two different types of human antibodies
18. Spontaneous inhibitors of FVIII: Kinetics of inactivation of human and porcine FVIII
19. Cross reactivity of human factor VIII allo and auto-antibodies to pFVIII is similar
20. Factor VIII inhibitors
21. Anti-idiotypio suppression of autoantibodies to factor VIII (Antihaemophilic factor) by high dose intravenous gammaglobulin
22. Variable (V) region-mediated control of autoreactivity to factor VIII
23. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin
24. Origin of anti-idiotypic activity against factor VIII autoantibodies in pools of normal human immunogiobulin G (IVIG)
25. Neutralising anti-idiotype antibodies to factor VIII inhibitors following desensitization in patients with hemophilia A
26. Acquired hemophilia: Natural history study on 16 patients with factor VIII inhibitors receiving little or no therapy
27. A survey of 215 non-hemophilic patients with inhibitors to factor VIII
28. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
29. A more uniform measurement of factor VIII inhibitors
30. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: Improved specificity and reliability
31. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation
32. The natural history of the immune response to exogenous factor VIII in severe haemophilia A
33. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors
34. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
35. Safety profile of porcine factor Will and its use as hospital and home-therapy for patient with haemophilia A and inhibitors: The results of an international survey
36. Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party
37. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study
38. The Mayo Clinic surgical experience with recombinant factor VIIa (rFVIIa) in patients with congenital hemophilia A and B and high titer inhibitors
39. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high dose intravenous gammaglobulin
40. The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors
41. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin
42. A randomized trail of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies
43. Successful treatment of acquired hemophilia with oral immunosuppressive therapy
44. Acquired FVIII inhibitors-successful treatment with an oral outpatient regimen
45. Oral immunosuppressive therapy for acquired hemophilia
46. The treatment of acquired factor VIII inhibitors with cyclosporine
47. Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor
48. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus
49. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor
50. Post-partum factor VIII inhibitors: A review of the literature with special reference to the value of steroid and immunosuppresive treatment
51. Natural antibodies to factor VIII (antihemophilic factor) in healthy individuals